2020 American Transplant Congress » PTLD/Malignancies

3:15pm-3:27pm

MTOR-Inhibitor Regimens and Malignancy after Kidney Transplantation: Can the Risk Be Modified by Considering Human Leukocyte Antigen (HLA) Mismatch in Immunosuppression Selection?

A. Santos¹, C. Chen¹, K. Alquadan², M. A. Leghrouz², X. Wen³

3:27pm-3:39pm

Outcomes of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders: An Analysis of the UNOS/OPTN Database (1998 to 2019)

W. Cheungpasitporn¹, C. Thongprayoon², C. C. Jadlowiec³, W. J. Chon⁴, L. S. Cummings⁴, S. R. Katari⁴, N. Leeaphorn⁴

3:39pm-3:51pm

Patterns of Belatacept Use and Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) in US Kidney Transplant Recipients – Analysis of Organ Procurement and Transplantation Network (OPTN) Database

W. S. Cherikh¹, T. Kou², J. Foutz¹, A. Gomez-Caminero²

3:51pm-4:03pm

Long-Term Outcomes of Patients with Epstein-barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in an Expanded Access Program Study

S. Prockop¹, R. Reshaf², D. Tsai³, N. Bunin⁴, R. Abu-Arja⁵, K. Mahadeo⁶, W. Weng⁷, K. Van Besien⁸, D. Loeb⁹, S. Dwivedy Nasta¹⁰, E. Nemecek¹¹, M. Hiremath¹², S. Yue¹², Y. Sun¹², W. Navarro¹², S. Nikiforow¹³

4:03pm-4:15pm

Evaluation of Host Immune Responses to Epstein-Barr Virus in Lung Transplant Recipients

L. Zaffiri¹, J. E. Messinger², J. Yi², K. J. Weinhold², G. Ferrari², M. Luftig², S. M. Palmer¹

4:15pm-4:27pm

Genome-Wide Analysis of Epstein Barr Virus Identifies Variations in the Latency Gene EBNA3C That Are Associated with Post Transplant Lymphoproliferative Disorder

E. Maloney, J. Toh, S. M. Krams, C. O. Esquivel, O. M. Martinez

4:27pm-4:39pm

Role of CAR-T Cell Therapy in Post Transplant Lymphoproliferative Disorder

S. Krishnamoorthy, A. Malone, R. Delos Santos, H. Murad, T. Alhamad